[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100383858":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":40,"centralContacts":44,"locations":49,"responsibleParty":72,"collaborators":39,"id":74,"slug":39,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":39,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":39,"enrollmentInfo":82,"targetDuration":39,"studyType":85,"phases":86,"briefSummary":89,"conditions":90,"keywords":39,"overallStatus":52,"whyStopped":39,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Bionic Sight LLC","INDUSTRY",[8,14,18,22,26,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","BSO1 Cohort 1 dose",[13],"Drug: BS01",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","BS01 Cohort 2 dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","BS01 Cohort 3 dose",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4","BS01 Cohort4 dose",[13],{"label":27,"type":10,"description":24,"interventionNames":28},"Cohort 5",[13],{"label":30,"type":10,"description":31,"interventionNames":32},"Cohort 6","Treat opposite eye",[13],[34],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","BS01","Non-replicating, rep\u002Fcap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)",[9,15,19,23,27,30],null,[41],{"name":42,"affiliation":5,"role":43},"Sheila Nirenberg, PhD","STUDY_DIRECTOR",[45],{"name":46,"role":47,"phone":39,"phoneExt":39,"email":48},"Minako Koga","CONTACT","mkoga@kmphc.com",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"New Jersey Retina","RECRUITING","Teaneck","New Jersey","07666","United States",{"type":58,"coordinates":59},"Point",[60,61],-74.01597,40.8976,{"lat":61,"lon":60},[64,69],{"name":65,"role":47,"phone":66,"phoneExt":67,"email":68},"Lauryn Onkendi","(201)837-7300","opt. 4","lonkendi@njretina.com",{"name":70,"role":71,"phone":39,"phoneExt":39,"email":39},"Paul Hahn, MD","PRINCIPAL_INVESTIGATOR",{"type":73,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100383858",false,"NCT04278131","BS01 in Patients With Retinitis Pigmentosa","Phase 1\u002F2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa","Inclusion Criteria:\n\n* Confirmed diagnosis of retinitis pigmentosa\n* At least one eye with vision no better than 20\u002F160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.\n\nExclusion Criteria:\n\n* Prior receipt of any AAV gene therapy product\n* Large amplitude nystagmus","ALL","18 Years",{"count":83,"type":84},20,"ESTIMATED","INTERVENTIONAL",[87,88],"PHASE1","PHASE2","A Phase 1\u002F2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa",[91],"Retinitis Pigmentosa","2026-01-21",{"date":94,"type":95},"2026-01-23","ACTUAL",{"date":97,"type":95},"2020-02-06",{"date":99,"type":84},"2029-12-30",{"name":5,"class":6},1]